Atomoxetine Capsules Nationwide Recall for N-Nitroso Impurity Above FDA Limits
Glenmark Pharmaceuticals is recalling 39,168 bottles of Atomoxetine 100 mg capsules nationwide due to manufacturing deviations that resulted in N-Nitroso impurity exceeding FDA recommended limits. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II pharmaceutical recall for N-Nitroso Atomoxetine impurity above FDA recommended limits, which constitutes a risk-of-harm product given the carcinogenic potential of nitroso compounds. The source reports no illnesses or injuries, placing the score at the rubric maximum of 3 for risk-of-harm products without reported harm.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling 39,168 bottles of Atomoxetine Capsules, USP 100 mg, distributed nationwide. The affected bottles are identified by lot numbers 19234955, 19234956 (expiring 11/2025), 19240971 (expiring 2/2026), and 19241864 (expiring 4/2026), with NDC 68462-271-30.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations that resulted in the presence of N-Nitroso Atomoxetine impurity above FDA recommended limits. N-Nitroso compounds are a class of chemicals of concern in pharmaceutical manufacturing.
This prescription medication may have been dispensed to patients nationwide through pharmacy channels. Patients currently taking this medication should not stop taking it without consulting their healthcare provider, as abruptly discontinuing atomoxetine can have health consequences.
Patients with affected lot numbers should contact their pharmacy or healthcare provider to discuss their options, which may include exchanging their medication for an unaffected lot. Healthcare providers and patients can report adverse events to the FDA through MedWatch.
The recalled product
- Product
- ATOMOXETINE (ATOMOXETINE)
- Brand
- ATOMOXETINE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Affected units
- 39,168
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot Numbers: 19234955
- 19234956
- Exp.: 11/2025
- 19240971
- Exp.: 2/2026
- 19241864
- Exp.: 4/2026.
UPCs (7)
- 0368462265307
- 0368462270301
- 0368462267301
- 0368462271308
- 0368462268308
- 0368462269305
- 0368462266304
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same brand · ATOMOXETINE
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- HighAtomoxetine 40 mg Capsules Recalled for N-Nitroso Impurity Above Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Prescription Capsules Recalled for Impurity Above FDA Recommended Level
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled for Elevated Nitrosamine Impurity
FDA (Drugs) · 2025-02-26
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · nitroso impurity
See all →- HighCinacalcet tablets recalled for nitroso impurity above FDA limits
FDA (Drugs) · 2024-11-06
- HighPrescription Duloxetine 60 mg capsules recalled for N-nitroso impurity
FDA (Drugs) · 2024-05-15
- HighAccuretic tablets recalled for N-nitroso impurities exceeding safe limits
FDA (Drugs) · 2022-04-13